MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials.
The clinical trials are a world first with approvals for take home use of MindBio’s LSD-microdosing treatment. The initial Phase 2a open-label trial will assess the treatment in patients with major depressive disorder for eight weeks.
MindBio’s LSD-microdosing clinical trials to date have yielded positive top line data, such as improved quality of sleep, including REM and total time of sleep, and statistically significant enhancements in subjective feelings of wellness, creativity, happiness, social connectivity and energy. Participants in the LSD-microdosing group also reported statistically significant feelings of being less angry and less irritable.
MindBio has developed proprietary formulations for microdosing including safe delivery solutions for ease of prescription and safe home use and a digital intervention for monitoring and collecting live biometric data while clinical trial participants take their LSD-microdoses at home.
The Company’s Big Data strategy is to commercialize microdosing treatments with a package of proprietary solutions for safe and effective at home use of psychedelics.
In a statement, Justin Hanka, co-founder and CEO of MindBio, said the positive data we have collected to date is highly encouraging for targeting depressed patients with diminished mood and disrupted sleep.
